July 14th 2016
The statistics show you are much more likely to encounter an independent oncology practice in Alaska than in New Hampshire.
The Centers for Medicare & Medicaid Services is wavering on its commitment to the Medicare reform package passed in 2015, based on widespread concerns that the changes may be unwieldy and could increase the pace at which smaller physician practices are being forced into mergers.
July 12th 2016
Many oncology practices were motivated to join the Oncology Care Model in order to keep up with the evolution of value-based care. But when the Center for Medicare & Medicaid Innovation started telling practices that their applications had been accepted, it was panic time for some.
June 30th 2016
A year after announcing its intention to launch the Oncology Care Model alternative payment plan for oncology care, The Centers for Medicare & Medicaid Services said it has 196 practices enrolled across the United States and that the official start date is Friday, July 1.
June 23rd 2016
The Department of Health and Human Services has turned down a request to override the patent for prostate cancer drug enzalutamide (Xtandi) so that it can be sold to a broader base of patients at a reduced price.
June 14th 2016
Two researchers have challenged the notion that money can be saved by packaging medications in sizes that conform more closely to patient weight and dosing needs.
June 13th 2016
Cigna's new policy is an extension of a previous Cigna requirement for the use of certified genetic counselors for breast, ovarian, and colorectal cancer genetic tests.
June 12th 2016
Incoming generic and biosimilar substitutes for dominant, brandname hematology drugs may lead to less costly treatment, but a lot will depend on the quality and supply of these new products,
June 10th 2016
ASCO's value framework tool for scoring drugs evaluated in trials has been upgraded to address more than 400 comments—mainly, responses to a survey—made by physicians and others.
June 9th 2016
Florida Cancer Specialists & Research Institute has honed its merger strategy into a finely tuned regimen that goes from due diligence to planning to implementation and follow-up, all in a period as short as 120 days.
June 6th 2016
Researchers who set out to understand the affordability of cancer drugs across the globe concluded that lower prices in some poorer countries don’t equate to better access.
June 2nd 2016
The global cost of cancer therapies shot up to $107 billion in 2015, an 11.5% rise from the $100 billion 2014 total for oncology therapeutics and supportive care drugs.
May 31st 2016
Hematological practices can expect a slate of new generics to replace long-established brand drugs going off patent, as well as new blockbuster blood therapies that will significantly improve the treatment of some malignancies.
May 18th 2016
The American Board of Internal Medicine has promised to roll out a series of short assessments that could potentially be taken in the privacy of one’s home or office and via an open book exam.
May 17th 2016
May 11th 2016
The Evidence Blocks developed by the National Comprehensive Cancer Center make up one of the most ambitious attempts so far to incorporate data from multiple platforms to create a resource with broad applicability for the healthcare community.
May 10th 2016
Oncology practices may soon find themselves working directly with employers on benefits and treatment strategies.
May 5th 2016
Members of Congress on both sides of the aisle have responded to urgings from the oncology sector that they join in the effort to quash a proposal to change the rule on physician pay under Medicare Part B.
May 1st 2016
Enzalutamide (Xtandi) pricing heightens the likelihood of pre-authorization requirements and cost-sharing arrangements that may be financially burdensome, ruinous, or simply impossible to meet.
April 15th 2016
Members of the Community Oncology Alliance have issued a call to arms to spur a greater lobbying effort to stop a plan by The Centers for Medicare & Medicare Centers to implement a drug reimbursement change under Medicare Part B.